AOD-9604 timeline: what the research actually shows

AOD-9604 is a fragment of human growth hormone engineered to isolate the fat-metabolism region without the broader growth-hormone effects. It is worth being direct about its evidence base before any timeline, since it is weaker than most other compounds covered in this series.

What the research actually shows

AOD-9604 went through human obesity trials that were discontinued after failing to show a strong enough effect against placebo to support approval. That is a meaningfully different evidence picture than the GLP-1 compounds on this site, which have large published trials showing double-digit percentage weight change.

What gets reported anyway

Community reports describe subtle changes in fat metabolism markers over several weeks of use, generally framed as modest rather than dramatic, which is broadly consistent with the trial data not showing a strong standalone effect.

Common questions

Why include a compound with weak trial data at all? Because being upfront about which compounds have strong evidence and which do not is part of what this site is for. AOD-9604's own trial history is the most useful thing to know about it.

For mechanism, dosing reference and citations, see the AOD-9604 reference page.